Adjunctive treatment with high-titre convalescent plasma in severely and critically ill COVID-19 patients – a safe but futile intervention. A comparative cohort study

BACKGROUND: Convalescent plasma (CP) containing antibodies derived from coronavirus disease 2019 (COVID-19) survivors has been proposed as a promising therapeutic option for severe COVID-19. METHODS: In our intensive care unit (ICU), 55 patients (46 male, median age 61 years) with PCR-confirmed COVI...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Infect Dis (Lond)
Asıl Yazarlar: Hoepler, Wolfgang Paul, Weidner, Lisa, Traugott, Marianna Theresia, Neuhold, Stephanie, Meyer, Elias Laurin, Zoufaly, Alexander, Seitz, Tamara, Kitzberger, Reinhard, Baumgartner, Sebastian, Pawelka, Erich, Karolyi, Mario, Grieb, Alexander, Hind, Julian, Laferl, Hermann, Friese, Emanuela, Wenisch, Christoph, Aberle, Stephan Walter, Aberle, Judith Helene, Weseslindtner, Lukas, Jungbauer, Christoph
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Taylor & Francis 2021
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8220442/
https://ncbi.nlm.nih.gov/pubmed/34128763
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/23744235.2021.1940271
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller